Healthcare Industry Insights

Wednesday, 28 October 2020

Ovarian Cancer Drugs Market Trends, Growth Opportunities and Overview Report

The global Ovarian Cancer Drugs Market size is expected to be valued at USD 4.5 billion by 2022, as per a new report by Grand View Research, Inc., expanding at a CAGR of 23.7% during the forecast period. The growth of the market is largely driven by factors such as increased adoption of novel drugs and presence of strong pipeline. Rising incidence of ovarian cancer due to growing geriatric population and unhealthy lifestyles is providing an upthrust to the market.

Ovarian cancer accounts for 3.0% of all malignant tumors among women and 6.0% of all femaledeaths due to cancer. Ovarian cancer accounted for 235,200 new cases and 140,000 deaths worldwide in 2016 with the highest incidence being reported in North America and Europe.

Introduction of non-platinum based PARP inhibitors and VEGF inhibitors in second and third-line settings has changed the treatment regime for ovarian cancer dramatically. Several biologic and small-molecule therapies including antibody drug conjugates (ADC) in development are estimated to have a major impact on ovarian cancer treatment spectrum.

Request a sample copy or view summary of this report@
https://www.grandviewresearch.com/industry-analysis/ovarian-cancer-drugs-market

Further key findings from the report suggest:

EU5 is projected to be the second largest market with more than 10.0% share in 2022, owing to increasing ovarian cancer incidence and approval of PARP inhibitors
Key players in the industry are focusing on collaborations for development, broader product portfolios, and regional expansion in emerging markets to increase their market share
Combination regimens and pipeline breakthroughs, specifically those including checkpoint inhibitors such as Roche’s Tecentriq and Pfizer’s Bavencio, are poised to be the upcoming milestones for ovarian cancer treatment
PARP inhibitors are anticipated to be the fastest growing drug class in the ovarian cancer market through the forecast period. Factors such as continued uptake of approved PARP inhibitors owing to their superior efficacy, long treatment duration, and considerable number of treatment opportunities in first-line advanced settings are likely to propel the growth of the drug class.
Although angiogenesis inhibitors accounted for the majority of shares in the market in 2016, the drug class is expected to capture a marginal share in 2022 owing to increasing competition from PARP inhibitors and novel pipeline products
Out of 78 drugs in the pipeline for ovarian cancer, 11 drugs are in Phase III, 29 in Phase II and the remaining in Phase I and pre-clinical trials
A greater understanding of tumor microenvironment is estimated to occur, which would further drive successful development of new patient-specific therapies through the forecast period
Late-stage pipeline includes novel drugs such as ImmunoGen’s mirvetuximab soravtansine and Vascular Biogenics’ VBL-111.

About Us:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Tuesday, 27 October 2020

Gastrointestinal Therapeutics Market by Takeda Pharmaceuticals, Valeant Pharmaceuticals, Allergan plc, and Bayer AG

The global Gastrointestinal Therapeutics Market size is expected to reach USD 65.1 billion by 2025, according to a new report by Grand View Research, Inc., registering a 6.6% CAGR during the forecast period. Growing geriatric population prone to gastrointestinal indications is one of the key factors anticipated to contribute to market growth. According to a report by WHO, colon cancer caused nearly 694,000 deaths in 2014.

Growing geriatric population, especially in emerging economies, is expected to drive market growth over the coming years. Furthermore, initiatives undertaken by the Centers for Disease Control and Prevention (CDC) to promote cancer screening nationwide is expected to boost market growth over the forecast period. The Division of Cancer Prevention and Control (DCPC) supports National Colorectal Cancer Action Campaign (NCCCP) and provides funds to aid research studies and implement strategies to control colorectal cancer. This increase in initiatives for screening is expected to fuel sales of therapeutics and present lucrative growth opportunities to the market.

Request a sample copy or view summary of this report@
https://www.grandviewresearch.com/industry-analysis/gastrointestinal-therapeutics-market

Further key findings from the report suggest:

Based on product type, the branded drugs segment dominated in 2016 owing to high potency drugs such as biologics and proton pump inhibitors. High growth of branded drugs over recent years is a result of positive patient outcomes and synergistic effect of various drugs used in conjunction in the treatment regimen
Generics are expected to expand at a lucrative CAGR owing to their high cost-efficiency and rising number of patent expirations
Ulcerative colitis accounted for the second-largest share in terms of application in 2016 owing to high clinical urgency to curb growing prevalence of ulcerative colitis
The others segment, which includes constipation, nausea, and pancreatic insufficiency, accounted for the largest share by application in 2016. This is a consequence of consistent efforts by government organizations for promoting awareness and enhancing management of these conditions
The Crohn’s disease segment is expected to grow at a lucrative rate over the coming years due to presence of extensive pipeline products in later stages of clinical trials
Retail pharmacy accounted for the largest share by way of distribution channel in 2016 owing to high accessibility to retail stores and affordability. Online pharmacies are anticipated to witness lucrative CAGR as they usually offer price discounts on bulk purchases.

About Us:

Rare Hemophilia Factors Market: Key Growth Drivers, Challenges, Leading Key Players Review

The global Rare Hemophilia Factors Market size is anticipated to reach USD 336.3 million by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 5.1% during the forecast period. Several factor concentrates gaining marketing approvals from regulatory bodies such as the U.S. FDA are expected to provide a significant push to the market. In addition, growing adoption of prophylaxis treatment by patients is expected to boost the growth of the market in coming years. Patients with severe rare hemophilia factor disorders are recommended prophylactic treatment to avoid bleeding episodes and improve quality of life.

Favorable government initiatives and mandates to increase diagnosis and treatment rates are escalating the growth of the market. For instance, the U.S. Congress enacted the Orphan Drug Act (ODA) in 1983. From 1983 to 2015, around 3,647 drugs were designated the status of orphan drugs and 554 drugs were approved by the U.S. FDA. Several key market players in the market are focusing on R&D to launch new products and solutions for the treatment of rare hemophilia factor disorders. For instance, in October 2015, FDA approved Coagadex for treatment of hereditary factor X deficiency. Introduction of new factor concentrates is likely to bolster market growth over the forecast period.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/rare-hemophilia-factors-market

Further key findings from the study suggest:

Based on type, factor VII accounted for the largest share in 2016, owing to higher prevalence of this deficiency
Factor concentrates is anticipated to be the most promising segment, registering a CAGR of 5.7% over the forecast period. This type of treatment is considered to be the safest and most effective treatment for rare hemophilia factor disorders
Fresh frozen plasma is estimated to command just over 53.0% of the market value by 2025
Asia Pacific rare hemophilia factors market is expected to exhibit the highest CAGR of over 5.5% during the same period. The growth of the region can be attributed to wide base of population and high number of consanguineous marriage
Some of the key players in the market are Novo Nordisk; Biogen; Bayer healthcare; Pfizer, Inc.; Baxalta; CSL Behring; and Bio Products Laboratory Ltd.

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

South Africa Hemodialysis & Peritoneal Dialysis Market by Fresenius Medical Care AG & Co. KGaA; B.Braun Avitum AG

The South Africa Hemodialysis & Peritoneal Dialysis Market size is anticipated to reach USD 847.2 million by 2025, according to a new report by Grand View Research, Inc. Rising incidence of end-stage renal disease (ESRD) is likely to drive the market to register a 7.1% CAGR during the forecast period.

Sedentary lifestyle, lack of exercise, alcohol consumption, and an increase in the incidence of diabetes and high blood pressure are driving the occurrence of ESRD, which is expected to support market growth. According to data by the Clinical Kidney Journal, the prevalence of chronic kidney disease in Africa was about 13.9% in 2016. An article published in the NCBI finds that the most common cause of ESRD is an increase in the prevalence of obesity and diabetes.

Dialysis and transplantation are two options available to patients suffering from severe kidney damage or kidney failure. The low availability of kidney donors is propelling the demand for dialysis. According to statistics provided by eNews Channel Africa, in 2016, about 2,096 patients were awaiting kidney transplants at Gauteng, a northern province of South Africa. This scenario is expected to remain unchanged over the forecast period, thereby acting as a major driver for the hemodialysis and peritoneal dialysis market.

Request a free sample copy or view report summary: South Africa Hemodialysis & Peritoneal Dialysis Market Report

South Africa Hemodialysis & Peritoneal Dialysis Market Report Highlights

Hemodialysis has been identified as the largest segment by type as the duration of treatment is shorter than that of peritoneal dialysis
By product, the services segment accounted for the largest share owing to the introduction of new dialysis centers, treatment options, and software
On the basis of end use, the home-based segment is poised to exhibit the fastest growth rate thanks to advantages of convenience, cost-effectiveness, and time flexibility offered by home-based dialysis
Various industry participants offer a wide portfolio of products for dialysis. Key players include Fresenius Medical Care AG & Co. KGaA; B.Braun Avitum AG; NIPRO Medical Corporation; DaVita, Inc.; and Baxter
Strategic initiatives such as mergers and acquisitions are anticipated to help market players in expanding their presence and staying competitive in the industry
In August 2017, Fresenius Medical Care signed an agreement to acquire NxStage Medical, Inc. The acquisition was aimed at expanding the product portfolio of the former, along with its client base and geographic foothold.

About Grand View Research

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Thursday, 22 October 2020

Veterinary Imaging Market: Growth Factors & Competitive Analysis, 2026

The global Veterinary Imaging Market size is expected to reach USD 3.3 billion by 2026, according to a new report by Grand View Research, Inc.expanding at a CAGR of 6.8% over the forecast period.The veterinary medicine field experienced immense technological developments in the last 20 years. Various technologies of human medical practice are being adopted for diagnosis and treatment of animals. Advancements in technologies are expected to fuel growth. For instance, launch of portable imaging equipment with battery charge is propelling the adoption of these systems in the following years.

Magnetic resonance imaging (MRI) and ultrasound analysis are some of the advanced technologies. MRIs are effective in the prognosis of human neurological disorders. These days, veterinarians are using MRIs for the examination of animal brains. This technology also helps in diagnosing soft tissues and orthopedic structure of an animal’s body. MRI has applications in cardiology for studying heart diseases.

Imaging devices help veterinarians and technicians in the diagnosis and management of zoonotic diseases. These instruments also assist in the diagnosis of injuries. Increasing adoption of advanced technologies coupled with growing awareness about animal health are some of the factors expected to propel market growth in the coming years. For example, University of Pennsylvania’s School of Veterinary Medicine was the first to use EQUIMAGINE, a diagnostic tool for horses. This device has 2 imaging C-arms that help in scanning all body parts of a horse. It also captures 2D CT images. This system is also currently being used in the diagnosis of diseases that affect horses.

Request a sample copy or view summary of this report @
https://www.grandviewresearch.com/industry-analysis/veterinary-imaging-market

Further Key Findings From the Study Suggest:

Increasing demand for minimally invasive diagnostic tools to reduce mortality and morbidity is anticipated to fuel the market growth.
Instruments held the dominant share owing to their increasing adoption in reference laboratories and other animal healthcare facilities
The MRI segment is expected to witness lucrative growth in the coming years owing to rising awareness about their benefits in animal disease diagnosis
Multi-slice CT scan systems are anticipated to gain popularity over the forecast period
Small companion animals held the dominant share as of 2018 owing to increasing adoption of pets and concern about their well-being
Veterinary hospitals accounted for the largest revenue share as of 2018 due to increase in adoption of imaging devices in animal health care facilities
The North America veterinary imaging market held the dominant share as of 2018 owing to increasing number of animal healthcare settings and awareness among pet owners in this region
Asia Pacific regional industry is expected to grow at a lucrative CAGR owing to increase in the number of veterinary care facilities and investments in animal healthcare
IDEXX Laboratories, Inc.; SOUND; GE Healthcare; and Toshiba Corporation held the dominant share of the market owing to their wide offerings of technologically advanced products and regional presence
Competitors are adopting strategies such as launch of new products, mergers & acquisitions, and regional expansion to gain competitive advantage

Bioresorbable Coronary Stents Market – Top Companies : BIOTRONIK, Meril Lifesciences Pvt. Ltd., Abbott, Elixir Medical Corporation, REVA Medical

Anticipated as well as recently launched global Bioresorbable Coronary Stents Market size will trigger a revenue increase to USD 247 million by 2025. At a CAGR of 15% according to a new report by Grand View Research, Inc., better device attributes of second-generation coronary stents will provide the ascending push to this market.

Bioresorbable stents are intended majorly for the young adult population, whereby these individuals are enabled with a normal functioning artery following complete resorption of the dissolvable devices.Lifestyle diseases and prevalence of associated risk factors underpin the growth in atherosclerosis-related cardiac events. This drives the global disease prevalence in young adults as well as the high volume of elective Percutaneous Coronary Interventions (PCI).

What sets the second-generation bioresorbable coronary stents apart? – Learning from past mistakes, manufacturers have developed new generation bioresorbable with thinner strut thicknesses, faster resorption times, and better radial force. Amaranth, with a single-minded focus on strut thickness, has developed three such devices. Each with a thinner strut. The latest, Magnitude boasts of 100 microns.

Another factor providing a fillip to this market is the less-invasive nature of PCIs as compared to coronary artery bypass grafting, resulting in their high elective procedure volume. In most parts of the world, lack of auditing to check inappropriate surgeries drives the number of coronary stenting procedures. Hence, this market is expected to witness growth due to the high volume of elective PCI, particularly in APAC and Europe.

Request a sample copy or view summary of this report@
http://www.grandviewresearch.com/industry-analysis/bioresorbable-coronary-stents-market

Further Key Findings From the Study Suggest:

Europe region is the major contributor for the bioresorbable stents market in 2016. Subsequent to withdrawal of the bioresorbable Absorb BVS, emergence of CE-approved bioresorbable stents hold strong growth prospects for greater sales in the member countries.
APAC follows Europe with almost 30% segment share and is expected to record the fastest growth in the future
Absorb BVS, among the key brands, engendered the highest sales revenue in 2016, while Absorb 2^nd generation device will supersede the sales of its rival devices toward the end of the forecast period
North America trails behind as the smallest revenue generator against leading counterparts, Europe and APAC, in this bioresorbable coronary stents market. Downfall of Abbott’s Absorb BVS, the only approved FDA device, is the underlying reason for the small segment share in the U.S. region.
Key players in this space include BIOTRONIK, Meril Lifesciences Pvt. Ltd., Abbott, Elixir Medical Corporation, REVA Medical, Arterial Remodeling Technologies, and Amaranth Medical
Strategic efforts undertaken by the companies to gain a higher market share center on bioresorbable coronary stents development. Companies targeting the clinical pipeline have developed second-generation bioresorbable products with better design specifications, such as devices with thinner strut thicknesses and faster absorption rates that gain comparability with the gold standard, drug-eluting metallic stents.

Collateral Ligament Stabilizer System Market: Growth Factors & Competitive Analysis, 2025

The global Collateral Ligament Stabilizer System Market size is expected to reach USD 2.36 billion by 2025, at a CAGR of 6.7% according to a new report by Grand View Research, Inc. An increase in the number of sports injuries and road accidents is expected to boost the adoption of Collateral Ligament Stabilizer System (CLSS). According to Stanford Children’s Health, around 3.5 million children aged 14 years and below are affected by some form of sport-related injury every year. This shows the potential demand for CLSS in the coming years.

Nearly one-third of all injuries affecting children arise due to sport-related activities. Sports Medicine Australia also estimated that 1 in 17 Australians suffer from sports trauma each year. According to the Zurich American Insurance Company, 62% of the injuries related to organized sports occur during practices. Thus, increasing sports-related injuries has resulted in the high demand for collateral ligament stabilizer systems.

According to WHO, every year nearly 1.25 million people die due to road accidents and about 20 to 50 million are injured. Thus, the rise in the number of road accidents is anticipated to heighten the adoption of CLSS.

Furthermore, the increasing geriatric population across the globe is another major factor propelling the growth of the CLSS market. According to a report published by the U.S. Census Bureau, Japan has the highest percentage of the aging population in the world. In 2015, about 26.6% of the population in Japan was aged 65 years and over, which accounted for nearly 33.7 million people.

Request a free sample copy or view report summary: Collateral Ligament Stabilizer System Market Report

Collateral Ligament Stabilizer System Market Report Highlights

The medial collateral ligament segment held the dominant share owing to the increase in the number of medial collateral ligament trauma resulting from sports or road accidents
The grade 2 injury segment is anticipated to grow at a lucrative CAGR due to the increase in the number of grade 2 injuries and recommendations by medical practitioners to use collateral ligament stabilizer systems in such cases
On the basis of end use, orthopedic clinics held the largest share of the collateral ligament stabilizer system market owing to the increase in the establishment of specialty clinics and the growing preference of patients for such clinics
Asia Pacific is anticipated to grow at a lucrative CAGR owing to the presence of high untapped opportunities, rising prevalence of chronic conditions such as osteoarthritis, and rise in the number of accident & trauma cases